생체흡수성 약제 용출형 관상동맥 스텐트 시스템 시장 : 세계 예측(2026-2032년)

The Bioabsorbable Eluting Coronary Stent System Market is projected to grow by USD 2.98 billion at a CAGR of 11.58% by 2032.

Bioabsorbable-Eluting Coronary Stent Systems: Executive Overview

Bioabsorbable-eluting coronary stent systems combine temporary mechanical support with controlled drug delivery and subsequent material resorption. Their clinical value proposition is to reduce long-term foreign-body presence while maintaining adequate vessel scaffolding during healing. Adoption is shaped by evidence quality, procedural reliability, regulatory requirements, reimbursement, physician familiarity, and patient selection.

Clinical Evidence and Device Design Are Reshaping the Landscape

The field is shifting from novelty-driven development toward evidence-led assessment of long-term outcomes, including restenosis, thrombosis, vessel healing, late lumen behavior, and repeat intervention. Design priorities include thinner struts, predictable degradation, controlled drug release, radial strength, deliverability, and radiographic visibility. Manufacturing consistency and post-market surveillance remain essential because small changes in polymer behavior, coating performance, or deployment characteristics can affect clinical performance.

Artificial Intelligence Is Strengthening Development, Selection, and Monitoring

Artificial intelligence can support nonclinical design optimization, imaging interpretation, lesion characterization, procedural planning, and identification of patients who may benefit from specific device strategies. Machine-learning tools can also assist with signal detection in clinical and post-market data, while generative methods may accelerate material and coating research. Effective deployment requires representative datasets, prospective validation, explainability, cybersecurity, and clear accountability for clinical decisions; AI should augment rather than replace physician judgment.

Regional Insights: Regulation, Infrastructure, and Evidence Determine Adoption

North America emphasizes rigorous clinical evidence, regulatory documentation, reimbursement justification, and advanced interventional infrastructure. Europe combines sophisticated cardiology services with increasingly demanding clinical, safety, and post-market requirements. Asia-Pacific presents substantial procedural diversity, with adoption influenced by local manufacturing capability, hospital purchasing systems, reimbursement, and training capacity. Latin America is shaped by public-private healthcare differences, import dependence, and uneven access to catheterization services. In the Middle East, tertiary-care investment and specialist concentration support adoption, while procurement and reimbursement vary across markets. Africa remains highly heterogeneous, with limited catheterization capacity and affordability acting as central constraints alongside opportunities to strengthen referral networks and specialist training.

Group Insights: Economic and Regulatory Blocs Create Different Operating Conditions

ASEAN markets differ in regulatory maturity, hospital financing, and access to interventional cardiology, making localized registration and distribution strategies important. BRICS economies combine large and diverse patient populations with varying domestic production, reimbursement, and procurement environments. The European Union requires alignment with regional regulatory and evidence expectations while retaining substantial national variation in purchasing and coverage. G7 systems generally place strong emphasis on comparative clinical value, quality systems, and post-market evidence. GCC countries often concentrate advanced cardiac care in major urban and tertiary institutions. NATO members are not a uniform healthcare bloc, but many share high expectations for supply resilience, device security, and sophisticated clinical infrastructure.

Country Insights: National Evidence and Access Conditions Shape Commercial Readiness

Australia and Canada emphasize evidence-based procurement and geographically dispersed care delivery. Brazil and Mexico face marked variation between private and public systems, with reimbursement and import processes influencing availability. China and India combine expanding interventional capacity with significant regional differences and growing interest in local manufacturing and clinical evidence. Japan and South Korea maintain advanced cardiovascular infrastructure and detailed regulatory expectations. France, Germany, Italy, Spain, and the United Kingdom assess devices through distinct national or regional pathways, with hospital procurement, health technology assessment, and post-market obligations affecting uptake. Russia's operating environment is influenced by regulatory, supply, and healthcare-access conditions. In the United States, adoption depends on regulatory clearance, physician confidence, payer recognition, hospital economics, and robust long-term clinical data.

Actionable Priorities for Leaders in Bioabsorbable Coronary Technologies

Industry leaders should prioritize well-designed comparative studies with meaningful long-term endpoints and transparent subgroup analysis. Device programs should integrate material science, coating control, imaging compatibility, delivery performance, and manufacturing validation from the earliest design stages. Regulatory strategies should be tailored to each jurisdiction, supported by traceable quality systems and active post-market surveillance. Commercial teams should develop physician training, imaging-based case selection, and health-economic evidence rather than relying on technical differentiation alone. Partnerships with hospitals, researchers, and data specialists can improve clinical adoption while responsible AI governance should address validation, bias, privacy, and human oversight.

Research Methodology: Evidence-Led Assessment of a Specialized Device Market

This executive summary uses a structured secondary-research framework focused on the clinical, technical, regulatory, healthcare-delivery, and reimbursement factors relevant to bioabsorbable-eluting coronary stent systems. Analysis should triangulate peer-reviewed studies, clinical-trial records, regulatory publications, professional-society guidance, procurement documentation, and publicly available healthcare data. Findings should be screened for source quality, publication date, geographic relevance, endpoint comparability, and potential conflicts. Because device performance and access conditions vary by indication and jurisdiction, conclusions should distinguish established evidence from emerging hypotheses and should be updated as long-term follow-up becomes available.

Conclusion: Evidence and Execution Will Define Sustainable Adoption

Bioabsorbable-eluting coronary stent systems address an important clinical ambition: providing temporary support and drug delivery without a permanent implant. Their sustainable advancement depends less on novelty than on dependable degradation, procedural usability, durable patient outcomes, credible comparative evidence, and consistent regulatory and manufacturing execution. Leaders that connect engineering discipline with physician education, patient selection, post-market learning, and region-specific access strategies will be better positioned to translate the technology's potential into responsible clinical use.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Bioabsorbable Eluting Coronary Stent System Market, by Product Type

• 7.1. Introduction
• 7.2. Balloon Expandable
• 7.3. Self Expandable

8. Bioabsorbable Eluting Coronary Stent System Market, by Drug Type

• 8.1. Introduction
• 8.2. Biolimus
• 8.3. Everolimus
• 8.4. Sirolimus

9. Bioabsorbable Eluting Coronary Stent System Market, by Polymer Type

• 9.1. Introduction
• 9.2. Poly-L-Lactic Acid
• 9.3. Polycaprolactone

10. Bioabsorbable Eluting Coronary Stent System Market, by Indication

• 10.1. Introduction
• 10.2. Acute Coronary Syndrome
  • 10.2.1. Non-ST Elevation Myocardial Infarction
  • 10.2.2. ST Elevation Myocardial Infarction
  • 10.2.3. Unstable Angina
• 10.3. Stable Angina

11. Bioabsorbable Eluting Coronary Stent System Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Cardiac Specialty Centers
• 11.4. Hospitals

12. Bioabsorbable Eluting Coronary Stent System Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Bioabsorbable Eluting Coronary Stent System Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Bioabsorbable Eluting Coronary Stent System Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Amaranth Medical Inc.
• 16.3. Arterial Remodeling Technologies SA
• 16.4. B. Braun Melsungen AG
• 16.5. Biosensors International Group Ltd
• 16.6. BIOTRONIK SE & Co. KG
• 16.7. Boston Scientific Corporation
• 16.8. Elixir Medical Corporation
• 16.9. Essen Technology Co. Ltd.
• 16.10. Kyoto Medical Planning Co. Ltd.
• 16.11. Lepu Medical Technology Co. Ltd.
• 16.12. Lifetech Scientific Co. Ltd.
• 16.13. Meril Life Sciences Pvt. Ltd.
• 16.14. MicroPort Scientific Corporation
• 16.15. REVA Medical LLC
• 16.16. Sahajanand Medical Technologies Private Limited
• 16.17. SINOMED
• 16.18. Terumo Corporation
• 16.19. Translumina Therapeutics LLP
• 16.20. Vascular Concepts Limited

17. Key Experts